secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2026-06-04T20:24:22+00:00
Accession:  0001628280-26-040812
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin shareholders approve 7.65M share increase in equity plan; all directors elected
--------------------------------------------------------------------------------

- Shareholders approved adding 7,650,000 shares to the 2017 Equity Incentive Plan.
- All ten director nominees were elected, including CEO Alexander Hardy.
- KPMG LLP ratified as BioMarin's independent auditor for FY 2026.
- Advisory say-on-pay proposal passed with 142.7M votes for and 21.3M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000162828026040812/0001628280-26-040812-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000162828026040812/bmrn-20260602.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-040812

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer